首页> 美国卫生研究院文献>ACS Medicinal Chemistry Letters >Discovery of a Novel Seriesof CRTH2 (DP2) ReceptorAntagonists Devoid of Carboxylic Acids
【2h】

Discovery of a Novel Seriesof CRTH2 (DP2) ReceptorAntagonists Devoid of Carboxylic Acids

机译:小说系列的发现CRTH2(DP2)受体受体不含羧酸的拮抗剂

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Antagonism of the CRTH2 receptor represents a very attractive target for a variety of allergic diseases. Most CRTH2 antagonists known to date possess a carboxylic acid moiety, which is essential for binding. However, potential acid metabolites O-acyl glucuronides might be linked to idiosynchratic toxicity in humans. In this communication, we describe a new series of compounds that lack the carboxylic acid moiety. Compounds with high affinity (Ki < 10 nM) for the receptor have been identified. Subsequent optimization succeeded in reducing the high metabolic clearance of the first compounds in human and rat liver microsomes. At the same time, inhibition of the CYP isoforms was optimized, giving rise to stable compounds with an acceptable CYP inhibition profile (IC50 CYP2C9 and 2C19 > 1 μM). Taken together, these data show that compounds devoid of carboxylic acid groups could represent an interesting alternative to current CRTH2 antagonists in development.
机译:CRTH2受体的拮抗作用代表了各种过敏性疾病的诱人靶标。迄今为止已知的大多数CRTH2拮抗剂具有羧酸部分,其对于结合是必不可少的。但是,潜在的酸代谢产物O-酰基葡萄糖醛酸苷可能与人类的特异毒性有关。在本文中,我们描述了一系列缺少羧酸部分的化合物。已鉴定出对受体具有高亲和力(Ki <10 nM)的化合物。随后的优化成功地降低了人和大鼠肝微粒体中第一种化合物的高代谢清除率。同时,对CYP亚型的抑制也进行了优化,从而得到了具有可接受CYP抑制特征(IC50 CYP2C9和2C19> 1μM)的稳定化合物。综上所述,这些数据表明,不含羧酸基团的化合物可以代表目前正在开发的CRTH2拮抗剂的有趣替代品。

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号